ATLANTA, GA – (Globe Newswire – July 24, 2024) – – Holzer & Holzer, LLC is investigating whether Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) complied with federal securities laws. On July 22, 2024, Allarity disclosed that it received a Wells Notice from the SEC concerning “the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company’s NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.” Following this news, the price of the Company’s stock dropped.

If you purchased Allarity stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at http://holzerlaw.com/case/allarity-therapeutics/ to discuss your legal rights.